AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9556010 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air) treatment
Number of subjects: 40
Study 9556010 — intervention group
Group type: COMPARATOR
Intervention: Control group (children born at term)
Number of subjects: 40
Study 7869468 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone alone
Number of subjects: 144
Study 7869468 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone plus 3 mg guanfacine
Number of subjects: 144
Study 7869468 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone plus 4 mg guanfacine
Number of subjects: 144
Study 7869468 — intervention group
Group type: COMPARATOR
Intervention: Control (Methadone)
Number of subjects: 144
Study 3122549 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nitroglycerin patch
Number of subjects: 13
Study 3122549 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 13
Study 31154664 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C increase
Number of subjects: 337
Study 29770756 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blueberries
Number of subjects: 9
Study 29770756 — intervention group
Group type: COMPARATOR
Intervention: Juiced blueberries
Number of subjects: 9
Study 27718280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary plus 400 mg daily vaginal progesterone (group B)
Number of subjects: 144
Study 27718280 — intervention group
Group type: COMPARATOR
Intervention: 400 mg daily vaginal progesterone (group A)
Number of subjects: 144
Study 24933496 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief telephone-based cognitive-behavioral therapy intervention
Number of subjects: 300
Study 24933496 — intervention group
Group type: COMPARATOR
Intervention: Usual services (Control)
Number of subjects: 300
Study 22513062 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 2% plus adrenaline 1:200,000 (group T)
Number of subjects: 88
Study 22513062 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% plus adrenaline 1:200,000 (group L)
Number of subjects: 88
Study 21261200 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and nutrition education intervention (n=195) through personal discussion sessions and lane approach
Number of subjects: 370
Study 21261200 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=175)
Number of subjects: 370
Study 18285545 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-risk group (35% of patients)
Number of subjects: 2169
Study 18285545 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-risk group (53% of patients)
Number of subjects: 2169
Study 18285545 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (12% of patients)
Number of subjects: 2169
Study 18285545 — intervention group
Group type: COMPARATOR
Intervention: Omission of preventive cranial irradiation in non-T-ALL medium-risk patients
Number of subjects: 2169
Study 18285545 — intervention group
Group type: COMPARATOR
Intervention: Comparison with previous trial ALL-BFM 90
Number of subjects: 2169
Study 15882226 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural educational intervention based on autoregulation theory
Number of subjects: 30
Study 15882226 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment based on instruction of proper prophylactic dental care
Number of subjects: 30
Study 12563046 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective head cooling with rectal temperature maintained at 35.0 degrees C
Number of subjects: 26
Study 12563046 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective head cooling with rectal temperature maintained at 34.5 degrees C
Number of subjects: 26
Study 12563046 — intervention group
Group type: COMPARATOR
Intervention: Normothermic control group
Number of subjects: 26
Study 10668583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (1 g b.i.d.)
Number of subjects: 50
Study 10668583 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (1 g t.i.d.)
Number of subjects: 50
Study 9080244 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer charting of physiological parameters
Number of subjects: 101
Study 9080244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotside display of computer data
Number of subjects: 101
Study 9080244 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer data with artifact removal
Number of subjects: 101
Study 8250520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa (mesalazine) 2 g/day
Number of subjects: 161
Study 8250520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 3472450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salt loading (normal diet + 200 mmol NaCl/day for 4 weeks followed by normal diet + 400 mmol/day for 1 week)
Number of subjects: 10
Study 3472450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30688673 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES)
Number of subjects: 340
Study 29380951 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sex hormone condition (gonadotropin releasing hormone antagonist, aromatase inhibitor, and placebo gel)
Number of subjects: 11
Study 29380951 — intervention group
Group type: COMPARATOR
Intervention: Testosterone add‐back condition (testosterone gel)
Number of subjects: 11
Study 24172767 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (dGTE)
Number of subjects: 19
Study 24172767 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 19
Study 22566311 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/d I-PHGG (fiber group)
Number of subjects: 60
Study 22566311 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo group)
Number of subjects: 60
Study 19946034 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 0
Study 17950101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose with amino acids
Number of subjects: 16
Study 17950101 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose without amino acids (control)
Number of subjects: 16
Study 15677624 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan/5‐FU/leucovorin (LV) (IFL)
Number of subjects: 795
Study 15677624 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaliplatin/5‐FU/LV (FOLFOX4)
Number of subjects: 795
Study 15677624 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaliplatin/irinotecan (IROX)
Number of subjects: 795
Study 15677624 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy following resection
Number of subjects: 795
Study 15677624 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-ablation (RFA)
Number of subjects: 795
Study 12121731 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum A toxin (100 IU in 4 ml of 9% saline)
Number of subjects: 13
Study 12121731 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (4 ml of 0.5%)
Number of subjects: 13
Study 10501652 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 24 microg + oxitropium bromide 200 microg
Number of subjects: 16
Study 10501652 — intervention group
Group type: EXPERIMENTAL
Intervention: oxitropium bromide + formoterol 24 microg
Number of subjects: 16
Study 10501652 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 12 microg + oxitropium bromide 200 microg
Number of subjects: 16
Study 10501652 — intervention group
Group type: EXPERIMENTAL
Intervention: oxitropium bromide + formoterol 12 microg
Number of subjects: 16
Study 10501652 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 12 microg
Number of subjects: 16
Study 10501652 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 24 microg
Number of subjects: 16
Study 10501652 — intervention group
Group type: EXPERIMENTAL
Intervention: oxitropium bromide
Number of subjects: 16
Study 7662601 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate (first dose)
Number of subjects: 10
Study 7662601 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate (second dose)
Number of subjects: 10
Study 2811943 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic prednisone (0.4 to 0.5 mg/kg for one month, gradually withdrawn over three months)
Number of subjects: 52
Study 2811943 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine treatment alone
Number of subjects: 52
Study 768965 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 0
Study 768965 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose
Number of subjects: 0
Study 768965 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30286300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT) executed twice a week
Number of subjects: 26
Study 30286300 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) and Continuous Endurance Training (CET)
Number of subjects: 26
Study 28619114 — intervention group
Group type: EXPERIMENTAL
Intervention: smartphone-based monitoring system including an integrated feedback loop and context-aware cognitive behavioral therapy (CBT) modules
Number of subjects: 400
Study 28619114 — intervention group
Group type: COMPARATOR
Intervention: standard treatment
Number of subjects: 400
Study 28619114 — intervention group
Group type: EXPERIMENTAL
Intervention: smartphone-based monitoring system
Number of subjects: 400
Study 25627322 — intervention group
Group type: EXPERIMENTAL
Intervention: Early application of the non-pneumatic anti-shock garment (NASG) at the Primary Health Center (PHC)
Number of subjects: 0
Study 25627322 — intervention group
Group type: COMPARATOR
Intervention: Later application of the non-pneumatic anti-shock garment (NASG) at the Referral Hospital (RH)
Number of subjects: 0
Study 23871290 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin thromboprophylaxis
Number of subjects: 3764
Study 21211064 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly reminder and motivational text messages
Number of subjects: 198
Study 21211064 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 198
Study 19064504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower energy density meals served over 2 days
Number of subjects: 26
Study 19064504 — intervention group
Group type: COMPARATOR
Intervention: Higher energy density meals served over 2 days
Number of subjects: 26
Study 16424989 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic linear cutting stapler used to divide short gastric vessels
Number of subjects: 56
Study 16424989 — intervention group
Group type: COMPARATOR
Intervention: Standard method (divided between hemostats and ligated)
Number of subjects: 56
Study 12939852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates and captopril
Number of subjects: 141
Study 12939852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates and enalapril
Number of subjects: 141
Study 12939852 — intervention group
Group type: COMPARATOR
Intervention: Nitrates and placebo
Number of subjects: 141
Study 12939852 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 141
Study 12939852 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 141
Study 12939852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 12939852 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of treatment, infarct location, and enzyme level
Number of subjects: 141
Study 11074202 — intervention group
Group type: EXPERIMENTAL
Intervention: PARAGON stent
Number of subjects: 688
Study 11074202 — intervention group
Group type: COMPARATOR
Intervention: Palmaz-Schatz stent
Number of subjects: 688
Study 9185459 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 12.5 micrograms.h‐1 (Group C, control, n = 7)
Number of subjects: 21
Study 9185459 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms.h‐1 (Group S2, n = 7)
Number of subjects: 21
Study 9185459 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms.h‐1 (Group C2, n = 7)
Number of subjects: 21
Study 8418700 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term endoscopic sclerotherapy
Number of subjects: 60
Study 8418700 — intervention group
Group type: COMPARATOR
Intervention: Elective shunt surgery
Number of subjects: 60
Study 3296637 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatonorm
Number of subjects: 21
Study 3296637 — intervention group
Group type: COMPARATOR
Intervention: Pituitary hGH
Number of subjects: 21
Study 29570594 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Blood-Flow Restricted Exercise (LI BFR)
Number of subjects: 10
Study 29570594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Training (HI)
Number of subjects: 10
Study 29570594 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Non-Blood-Flow Restricted Exercise (LI non-BFR)
Number of subjects: 10
Study 27199475 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly mass azithromycin distributions for trachoma for 1 year
Number of subjects: 24
Study 27199475 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 24
Study 24851679 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine treatment
Number of subjects: 72
Study 24851679 — intervention group
Group type: COMPARATOR
Intervention: Non-hydroxychloroquine
Number of subjects: 72
Study 22323387 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandio
Number of subjects: 30
Study 22323387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Ceram
Number of subjects: 30
Study 20637972 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-402 (0.015, 0.1, 0.5, 2.5, 12.5, 37.5, 188, 620, or 1860 microg/kg)
Number of subjects: 56
Study 20637972 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive vehicle)
Number of subjects: 56
Study 18622504 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 40
Study 18622504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15770115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (150 mg/day)
Number of subjects: 94
Study 15770115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 12451430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg once daily for 11 days
Number of subjects: 14
Study 12451430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10702654 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial pain assessment during hospitalization
Number of subjects: 177
Study 10702654 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month pain recollection
Number of subjects: 177
Study 10702654 — intervention group
Group type: EXPERIMENTAL
Intervention: High emotional distress group
Number of subjects: 177
Study 8938548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt
Number of subjects: 10
Study 1752602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (10 patients randomized to receive this treatment)
Number of subjects: 45
Study 1752602 — intervention group
Group type: COMPARATOR
Intervention: Hypoprolactinemic cycle group
Number of subjects: 45
Study 1752602 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperprolactinemic cycle group
Number of subjects: 45
Study 1752602 — intervention group
Group type: COMPARATOR
Intervention: Euprolactinemic cycle group
Number of subjects: 45
Study 7234826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (2,400 mg/day)
Number of subjects: 25
Study 7234826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolmetin (2,000 mg/day)
Number of subjects: 25
Study 7234826 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day)
Number of subjects: 25
Study 7234826 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg/day)
Number of subjects: 25
Study 7234826 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four tablets daily)
Number of subjects: 25
Study 31783597 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Foodis Lactobacillus)
Number of subjects: 50
Study 31783597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30024784 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 309
Study 30024784 — intervention group
Group type: COMPARATOR
Intervention: 7+3 (conventional cytarabine plus daunorubicin)
Number of subjects: 309
Study 28509517 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (oral health promotion package including pamphlet, baby toothbrush, fluoride toothpaste 1,000 mg/L, trainer cup)
Number of subjects: 92
Study 28509517 — intervention group
Group type: COMPARATOR
Intervention: Control One (only pamphlet)
Number of subjects: 92
Study 28509517 — intervention group
Group type: COMPARATOR
Intervention: Control Two (no intervention)
Number of subjects: 92
Study 24816536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (0.5 mg/kg)
Number of subjects: 101
Study 24816536 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 µg/kg)
Number of subjects: 101
Study 24816536 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 µg/kg)
Number of subjects: 101
Study 24816536 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 101
Study 22772951 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 199
Study 22772951 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin
Number of subjects: 199
Study 22772951 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment NLR
Number of subjects: 199
Study 22772951 — intervention group
Group type: EXPERIMENTAL
Intervention: High pretreatment NLR that declined after treatment
Number of subjects: 199
Study 19417230 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training exercises (squat, seated leg curl, stiff leg dead lift, single leg stiff leg dead lift, good morning, Russian curl)
Number of subjects: 34
Study 19417230 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training exercises
Number of subjects: 34
Study 19417230 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength matched resistance training exercises
Number of subjects: 34
Study 17196493 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular coracoid approach (IC group)
Number of subjects: 60
Study 17196493 — intervention group
Group type: COMPARATOR
Intervention: Axillary approach (AX group)
Number of subjects: 60
Study 15497667 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (clopidogrel bisulfate, 75 mg)
Number of subjects: 36
Study 15497667 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (originator product)
Number of subjects: 36
Study 11728786 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased alcohol consumption among women
Number of subjects: 354
Study 11728786 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 354
Study 9443770 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol daily for 8 weeks
Number of subjects: 12
Study 9443770 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg captopril twice daily for 8 weeks
Number of subjects: 12
Study 9443770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7946439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine treatment
Number of subjects: 4
Study 7946439 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR method
Number of subjects: 4
Study 3284267 — intervention group
Group type: EXPERIMENTAL
Intervention: halothane 0.5 MAC + 50% N2O
Number of subjects: 12
Study 3284267 — intervention group
Group type: EXPERIMENTAL
Intervention: enflurane 0.5 MAC + 50% N2O
Number of subjects: 12
Study 3284267 — intervention group
Group type: COMPARATOR
Intervention: halothane 1 MAC in oxygen
Number of subjects: 12
Study 3284267 — intervention group
Group type: COMPARATOR
Intervention: enflurane 1 MAC in oxygen
Number of subjects: 12
Study 29402954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone followed by 38% H2O2 (20 min)
Number of subjects: 45
Study 29402954 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% H2O2 followed by ozone
Number of subjects: 45
Study 29402954 — intervention group
Group type: COMPARATOR
Intervention: Control group: Air followed by 38% H2O2 (20 min)
Number of subjects: 45
Study 29402954 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 29402954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (before or after H2O2)
Number of subjects: 45
Study 27520090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at 45 mmHg
Number of subjects: 12
Study 27520090 — intervention group
Group type: COMPARATOR
Intervention: Blood loss (BL) of 1000 ml
Number of subjects: 12
Study 25002305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone application
Number of subjects: 24
Study 25002305 — intervention group
Group type: COMPARATOR
Intervention: Paper-based chart tool
Number of subjects: 24
Study 22739998 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI)
Number of subjects: 607
Study 22739998 — intervention group
Group type: COMPARATOR
Intervention: No epidural steroid injection (No-ESI)
Number of subjects: 607
Study 20877623 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd5 vaccine alone (1×10^10 or 1×10^11 particle units)
Number of subjects: 114
Study 20877623 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime - rAd5 boost
Number of subjects: 114
Study 20877623 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd5 vaccine alone
Number of subjects: 114
Study 20877623 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd5 vaccine alone or DNA prime - rAd5 boost
Number of subjects: 114
Study 19035857 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening with PSA (abnormal >4.0 ng/mL) and DRE
Number of subjects: 38349
Study 17169935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit and Strong! intervention
Number of subjects: 215
Study 14510719 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (400 microg bid)
Number of subjects: 20
Study 14510719 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (200 microg bid)
Number of subjects: 20
Study 10525751 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sulpiride
Number of subjects: 34